Abbott disclosed on Thursday that a cyberattack hit its cancer diagnostics business.

The medical device company said in a statement posted to its website that there was unauthorized access to a limited number of internal systems in its cancer diagnostics business. There was no impact on other Abbott businesses, sites or systems.

Abbott’s cancer diagnostics business includes Exact Sciences, which the company acquired in a $21 billion deal earlier this year. The legacy Exact Sciences systems are separate from Abbott’s, according to the statement.

“This does not impact any business operations, product or product availability, manufacturing or lab operations, or our ability to serve patients,” Abbott said. At this time, the company does not expect a material impact on the business or financial results.

Upon discovering the attack, Abbott contacted third-party cybersecurity experts and law enforcement, and an investigation is underway regarding the information accessed.

Abbott did not disclose what kind of information was accessed. The company declined to respond further to MedTech Dive’s request for comment regarding when the attack was discovered and what kind of information was accessed.

Abbott is one of several medtech companies to disclose a cyberattack in recent months. In March, Stryker experienced an attack that brought down its ordering, shipping and manufacturing for weeks and ate into its first-quarter earnings.

Stryker’s incident was followed by disclosures of cyberattacks from Intuitive, Medtronic, iRhythm and AdaptHealth.